Purchase this article with an account.
P. Velasco, O. Baca, R. Velasco, D. Viggiano, C. Cardona; Topic Cyclosporine "A" in the Management of Allergic Conjunctivitis . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3798.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To assess the efficiency of topic Cyclosporine "A" with two different concentrations in patients with mild to severe allergic conjunctivitis. Methods: This is a prospective, comparative and longitudinal study held at the Cornea Department. We stratified into 3 different groups: 1) Seasonal or Pereneal Allergic Conjunctivitis, 2) Vernal Keratoconjunctivitis, and 3) Atopic Keratoconjunctivitis, treated with cyclosporine "A" with a random concentration of 1 mg/ml (0.1%) and 2 mg/ml (0.2%), with a weekly photographic follow up, for at least a month. We assess the following symptoms: ocular grittines, ocular pain, watering, photophobia, itching, and foreign body sensation. Graduating them from absent, mild, moderate, or severe. We assess the following signs too: lid swelling, conjunctival congestion, papillary reaction, Trantas reaction, and superficial punctate keratitis (SPK). Those signs were compared with standard pictures and graduate from absent to severe. Results: We studied 18 patients: 5 in group One, 9 in group Two, and 4 in group Three. Three patients (16.7%) were intolerant to the treatment. The rest of them had satisfactory evolution with a 50% of symptomatic relief within the first week of treatment. Patients on group One had the best response to treatment. We found no difference between the 0.1% and 0.2% cyclosporine. Conclusions: The management of allergic conjunctivitis with topic cyclosporine "A" has a satisfactory evolution in 83.3% of the patients, with a 50% of symptomatic relief with the first week of treatment.
This PDF is available to Subscribers Only